Independent register of U.S. FDA drug recalls · updated Oct 11, 2026
RxRecalls Get alerts

Class II drug recalls - moderate risk

Class II means the product may cause temporary or medically reversible harm, and serious harm is unlikely. It is by far the largest recall class - most potency, dissolution and labeling problems land here.

14,535 recalls, newest first.

Class II · Moderate risk

Aripiprazole Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-283-10 D-0370-2023
Class II · Moderate risk

Aripiprazole Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-282-10 D-0369-2023
Class II · Moderate risk

Aripiprazole Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-281-10 D-0368-2023
Class II · Moderate risk

Aripiprazole Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-280-10 D-0367-2023
Class II · Moderate risk

Aripiprazole Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-279-10 D-0366-2023
Class II · Moderate risk

Aripiprazole Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-278-10 D-0365-2023
Class II · Moderate risk

Delsam Pharma's ARTIFICIAL TEARS

CGMP Deviations: All other lots of eye drops are being recalled due to CGMP Deviations because they were manufactured in the same facility under the same conditions as the lots found to be contaminated.

Ongoing cGMP deviation Global Pharma Healthcare Private Limited D-0922-2023
Class II · Moderate risk

Artificial Tears

CGMP Deviations: All other lots of eye drops are being recalled due to CGMP Deviations because they were manufactured in the same facility under the same conditions as the lots found to be contaminated.

Ongoing cGMP deviation Global Pharma Healthcare Private Limited NDC 79503-0101-15 D-0920-2023

Recalls by year